Feb 11 2009 |
more articles from
|
King Hussein Cancer Center adopts a number of smoking cessation treatments
Amman: In an effort to fight the smoking epidemic, and due to the increasing number of smokers in Jordanian that has now reached to 50% males and 18% females, King Hussein Cancer Center 's Smoking Cessation Clinic, and Pfizer - the world's largest research-based pharmaceutical company are cooperating to conduct the necessary studies to identify the reasons that drive people to smoke and look at individual varieties and conditions, in order to find suitable smoking cessation programs for each individual.
However, several international studies have been carried out to reveal a number of smoking cessation therapies and nicotine substitutes, such as: nicotine patches, nicotine gums or lozenges, and nicotine sprays; in addition to non-nicotine prescription medicines like Pfizer's latest breakthrough Champix® (Varenicline) which comes in tablet form and works by blocking nicotine from binding to the receptors in the brain.
On his behalf, Dr. Feras Hawari, Chief, Section of Pulmonary / Adult Care Department, and Director of Smoking Cessation Program at KHCC said: "It is important to benefit from the efforts put into medical and clinical studies by international pharmaceutical companies; therefore, we need to closely observe all the available smoking cessation therapies in Jordan, and study the efficacy of them locally before recommending the suitable smoking cessation program for each patient."
By involving a doctor, smokers can now improve their chances of quitting successfully through receiving effective counseling, proper assessment, and the right treatment for the right duration of time.
-Ends-
Quitting Tobacco
Tobacco dependence is a chronic, relapsing, physical and psychological condition which makes quitting both necessary and difficult to achieve. By involving a physician, a smoker improves his or her chance to quit successfully through proper assessment, treatment and support.
About Champix
Champix ® (Varenicline) is the first in a new class of treatment designed to help smokers reach their goal of quitting and staying quit. It is the first non-nicotine therapy specifically designed for smoking cessation by blocking nicotine from binding to the receptors in the brain that make tobacco so addictive.
About Pfizer Inc:
Founded in 1849, Pfizer is the world's largest research-based pharmaceutical company taking new approaches to better health.
© Press Release 2009
Zawya Comment Policy
-
Zawya encourages you to add a comment to this discussion. You agree that when you add content to this discussion your comments will not:
1.1 Contain any material which is libelous or defamatory of any person, is obscene, offensive, hateful or inflammatory or causes damage to the reputation of any person or organisation.
1.2 Promote sexually explicit material, violence, discrimination based on race, sex, religion, nationality, disability, sexual orientation or age or any illegal activity.
1.3 Be made in breach of any legal duty owed to a third party, such as a contractual duty or a duty of confidence.
1.4 Be threatening, abuse or invade another's privacy, or cause annoyance, inconvenience or needless anxiety.
1.5 Be used to impersonate any person, to misrepresent your identity or affiliation with any person, or be likely to deceive any person.
1.6 Give the impression that they represent Zawya.
1.7 Advocate, promote or assist any unlawful act such as (by way of example only) copyright infringement or computer misuse. - The content posted on www.zawya.com is created by members of the public. The views expressed are theirs and unless specifically stated are not those of Zawya. Zawya reserves the right to review all comments prior to posting and edit or delete any contribution, but Zawya is not responsible for and can not be held liable for any content posted by members of the public on www.zawya.com.
- Zawya is not responsible for the availability or content of any third party sites that are accessible through www.zawya.com. Any links to third party websites from www.zawya.com do not amount to any endorsement of that site by Zawya and any use of that site by you is at your own risk.
- By submitting your comment, you hereby give Zawya the right, but not the obligation, to post, air, edit, exhibit, telecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comments worldwide, in perpetuity.
Copyright © 2012 Zawya Ltd. All rights reserved. |
provided by www.zawya.com |
Post Your Comment